论文部分内容阅读
[目的]探讨莫西沙星治疗支原体肺炎的有效性和安全性。[方法]选择2009年10月～2010年10月间某院收治的80例支原体肺炎感染患者为研究对象,随机分为对照组和观察组,每组40例。对照组给予红霉素静脉滴注30mg/(kg.d),2次/d;观察组给予莫西沙星片,400mg/d,1次/d,治疗时间为7～14d。比较两组患者临床疗效、体征消失时间、住院时间及不良反应发生情况。[结果]观察组总有效率为96.0%,明显高于对照组80%,组间比较差异有统计学意义(χ2=4.11,P﹤0.05);观察组的咳嗽消失时间、退热时间、肺部啰音消失时间、住院时间均明显短于对照组,组间比较差异有统计学意义(P﹤0.05);观察组不良反应发生率5%,低于对照组12.5%,组间比较差异无统计学意义(χ2=0.63,P﹥0.05)。[结论]莫西沙星治疗支原体肺炎疗效确切,疗程短,不良反应少,值得临床进一步推广使用。
[Objective] To investigate the efficacy and safety of moxifloxacin in the treatment of mycoplasma pneumonia. [Method] Eighty patients with mycoplasma pneumoniae infection admitted in a hospital from October 2009 to October 2010 were selected as the research object and randomly divided into control group and observation group, 40 cases in each group. The control group was given erythromycin intravenously 30mg / (kg.d), 2 times / d; the observation group was given moxifaxacin tablets, 400mg / d, 1 / d, the treatment time was 7 ~ 14d. Clinical efficacy, signs of disappearance of time, hospital stay and adverse reactions were compared between the two groups. [Results] The total effective rate in the observation group was 96.0%, which was significantly higher than that in the control group (χ2 = 4.11, P <0.05). The cough disappearing time, The disappearance time and length of hospital stay were significantly shorter than those in the control group (P <0.05). The incidence of adverse reactions in the observation group was 5%, which was lower than that in the control group (12.5%). There was no significant difference between the two groups Statistical significance (χ2 = 0.63, P> 0.05). [Conclusion] Moxifloxacin is effective in treating mycoplasmal pneumonia with short course of treatment and few adverse reactions. It is worth further promotion and use in clinic.